Results 11 to 20 of about 26,198 (189)

Unfractionated Heparin and Low-Molecular-Weight Heparin in Sepsis: Anti-Inflammatory and Anticoagulant Effects Versus No Anticoagulation-A Propensity Score-Matched Analysis. [PDF]

J Clin Lab Anal
This propensity score‐matched study compared unfractionated heparin (UFH) and low‐molecular‐weight heparin (LMWH) in 1362 sepsis patients, finding that both significantly improved survival without increasing 90‐day bleeding risk. However, their therapeutic mechanisms differed: UFH demonstrated broader anti‐inflammatory effects by reducing IL‐6, IL‐8 ...
Chen P, Yao Y, Zhao B, An Y, Jiang J, Ma L, Mao E, Wang Y.   +7 more
europepmc   +2 more sources

Mechanism of Action and Pharmacology of Unfractionated Heparin [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2001
An updated statement by the American Heart Association (AHA) on the pharmacology and clinical use of heparin and low-molecular-weight heparin (LMWH) is published online at http://www.atvb.org and also appears in the June 19, 2001 issue of Circulation . The following is a summary of the AHA statement.
J, Hirsh, S S, Anand, J L, Halperin, V, Fuster   +3 more
openaire   +2 more sources

The Search for Replacements for Unfractionated Heparin [PDF]

Circulation, 2001
Antithrombotic therapy is central to the management of patients presenting with an acute coronary syndrome (ACS). In addition to powerful new antiplatelet therapies, multiple agents capable of inhibiting thrombin are now available to clinicians (Figure⇓). Figure 1. Activated coagulation cascade and platelet aggregation in patients with an ACS. A,
openaire   +2 more sources

THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents

Haematologica, 2019
Thromboembolism is a serious complication of induction therapy for childhood acute lymphoblastic leukemia. We prospectively compared the efficacy and safety of antithrombotic interventions in the consecutive leukemia trials ALL-BFM 2000 and AIEOP-BFM ALL
Jeanette Greiner, Martin Schrappe, Alexander Claviez, Martin Zimmermann, Charlotte Niemeyer, Reinhard Kolb, Wolfgang Eberl, Frank Berthold, Eva Bergsträsser, Astrid Gnekow, Elisabeth Lassay, Peter Vorwerk, Melchior Lauten, Axel Sauerbrey, Johannes Rischewski, Andreas Beilken, Günter Henze, Wolfgang Korte, Anja Möricke, for the THROMBOTECT Study Investigators   +19 more
doaj   +1 more source

Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials. [PDF]

PLoS ONE, 2015
Percutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa inhibitors has been shown to be as effective as unfractionated heparin plus routine glycoprotein IIb/IIIa inhibitors in preventing cardiac ischemic events, but with a
Anthony A Bavry, Islam Y Elgendy, Ahmed Mahmoud, Manoj P Jadhav, Tianyao Huo   +4 more
doaj   +1 more source

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients

EClinicalMedicine, 2021
Background: Coagulopathies are a major class among COVID-19 associated complications. Although anticoagulants such as unfractionated Heparin and Enoxaparin are both being used for therapeutic mitigation of COVID associated coagulopathy (CAC), differences
Colin Pawlowski, AJ Venkatakrishnan, Christian Kirkup, Gabriela Berner, Arjun Puranik, John C. O'Horo, Andrew D. Badley, Venky Soundararajan   +7 more
doaj   +1 more source

Beyond Unfractionated Heparin and Warfarin [PDF]

Circulation, 2007
Anticoagulants are widely used by cardiologists. Unfractionated heparin (UFH) and coumarins were discovered more than 60 years ago, and for more than 40 years, they have been the sole anticoagulant drugs available to clinicians.1,2 Now, in 2007, several new anticoagulants have been introduced, and many more are under clinical development.
Jack, Hirsh, Martin, O'Donnell, John W, Eikelboom   +2 more
openaire   +2 more sources

Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction

Clinical and Applied Thrombosis/Hemostasis, 2022
Objective The present study aimed to investigate the application safety of bivalirudin combined with ticagrelor in the emergency percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).
Zheng-Dong Wang, Yu-Xiang Chen, Ming Liu, Ping Li, Xiang-Wen Liang, Xian-Zhang Zhu, Wen-Chao Xie, Wang Liao   +7 more
doaj   +1 more source

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease

BMC Cardiovascular Disorders, 2001
Background Low molecular weight heparins hold several advantages over unfractionated heparin including convenience of administration. Enoxaparin is one such heparin licensed in the UK for use in unstable coronary artery disease (unstable stable angina ...
Milne Ruairidh, McGuire Alistair, Nicholson Tricia   +2 more
doaj   +1 more source

Subcutaneous Enoxaparin for Systemic Anticoagulation of COVID-19 Patients During Extracorporeal Life Support

Frontiers in Medicine, 2022
BackgroundExtracorporeal membrane oxygenation, with an inherent requirement for anticoagulation to avoid circuit thrombosis, is a key element in the treatment of respiratory failure associated with COVID-19.
Marion Wiegele, Daniel Laxar, Eva Schaden, Eva Schaden, Andreas Baierl, Mathias Maleczek, Mathias Maleczek, Paul Knöbl, Martina Hermann, Martina Hermann, Alexander Hermann, Christian Zauner, Johannes Gratz   +12 more
doaj   +1 more source